EUVIMEDEUVIMED entdecken
Open Access

Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence From Latin America

Humberto Martínez-Cordero iD, Camila Peña iD, Natalia Paola Schutz iD, Virginia Bove iD, Fiorella Villano iD, Cecilia Beltran, Javiera Donoso iD, Hernán López-Vidal, Macarena Alejandra Roa Salinas iD, Pablo Soto iD, Paola Ochoa iD, Patricio Duarte und 28 weitere

JCO Global Oncology · 2023

DOI: 10.1200/go.23.00182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2023. Verfasst von Humberto Martínez-Cordero und 39 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Nacional de Cancerología de Colombia, Bogotá, Colombia. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Multiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce. PATIENTS AND METHODS We analyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MM age 40 years or younger compared with 256 patients age 41-50 years and 957 patients age 51 years or older. RESULTS There were no statistical differences in sex, isotype, International Scoring System, renal involvement, hypercalcemia, anemia, dialysis, bony lesions, extramedullary disease, and lactate dehydrogenase (LDH). The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. Of the patients age 40 years or younger, only 53% received autologous stem-cell transplant (ASCT) and 71.1% received maintenance. There were no differences in overall survival (OS) in the three patient cohorts. In the multivariate analysis, only high LDH, high cytogenetic risk, and ASCT were statistically associated with survival. CONCLUSION In conclusion, younger patients with MM in Latin America have similar clinical characteristics, responses, and OS compared with the elderly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansAgedAdultMiddle AgedBortezomibThalidomideLatin AmericaTreatment OutcomeDexamethasoneAntineoplastic Combined Chemotherapy ProtocolsPrognosisCyclophosphamide

Substanzen

BortezomibThalidomideDexamethasoneCyclophosphamide

Autor:innen und Institutionen

  • Instituto Nacional de Cancerología de Colombia, Bogotá, Colombia.
  • Hospital Militar Central, Bogotá, Colombia.
  • Departamento de Hematología, Hospital Del Salvador, Santiago, Chile.
  • Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Asociación Española, Montevideo, Uruguay.
  • CASMU, Montevideo, Uruguay.

ORCID-Profile: Humberto Martínez-Cordero, Camila Peña, Natalia Paola Schutz, Virginia Bove, Fiorella Villano, Javiera Donoso, Macarena Alejandra Roa Salinas, Pablo Soto, Paola Ochoa, Guillermina Remaggi, Verónica Verri, Luis Darío Quiroga, Dorotea Fantl, Alejandro Ospina-Idárraga, Henry Idrobo, Guillermo Quintero, Omar Cantú-Martínez, David Gomez-Almaguer, Guillermo J Ruiz-Arguelles, Kenny Mauricio Galvez-Cárdenas, Luis Antonio Salazar, María Cynthia Fuentes-Lacouture, Jaime Valdes, Jule Vasquez, Alana von Glasenapp, Eloísa Riva

Zitieren

APA

Martínez-Cordero, H., Peña, C., Schutz, N. P., Bove, V., Villano, F., Beltran, C., Donoso, J., López-Vidal, H., Roa Salinas, M. A., Soto, P., Ochoa, P., Duarte, P., Remaggi, G., Corzo, A., Shanley, C., Lopresti, S., Orlando, S., Verri, V., Quiroga, L. D., …, & GELAMM (Grupo de Estudio Latinoamericano de Mieloma Múltiple) (2023). Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence From Latin America. JCO Global Oncology. https://doi.org/10.1200/go.23.00182

Vancouver

Martínez-Cordero H, Peña C, Schutz NP, Bove V, Villano F, Beltran C, et al. Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence From Latin America. JCO Global Oncology. 2023. doi:10.1200/go.23.00182

BibTeX
@article{MartnezCordero2023,
  author = {Martínez-Cordero, Humberto and Peña, Camila and Schutz, Natalia Paola and Bove, Virginia and Villano, Fiorella and Beltran, Cecilia and Donoso, Javiera and López-Vidal, Hernán and Roa Salinas, Macarena Alejandra and Soto, Pablo and Ochoa, Paola and Duarte, Patricio and Remaggi, Guillermina and Corzo, Ariel and Shanley, Claudia and Lopresti, Sergio and Orlando, Sergio and Verri, Verónica and Quiroga, Luis Darío and Fantl, Dorotea and Ramirez, Jhoanna and Ospina-Idárraga, Alejandro and Idrobo, Henry and Quintero, Guillermo and Gomez, Rigoberto and Cantú-Martínez, Omar and Gomez-Almaguer, David and Ruiz-Arguelles, Guillermo J and Galvez-Cárdenas, Kenny Mauricio and Salazar, Luis Antonio and Novoa-Caicedo, Isabella and Fuentes-Lacouture, María Cynthia and Spirko, Paola and Arbeláez, María Isabel and Pereira, Mario and Valdes, Jaime and Vasquez, Jule and von Glasenapp, Alana and Riva, Eloísa and GELAMM (Grupo de Estudio Latinoamericano de Mieloma Múltiple), GELAMM (Grupo de Estudio Latinoamericano de Mieloma Múltiple)},
  title = {Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence From Latin America},
  journal = {JCO Global Oncology},
  year = {2023},
  doi = {10.1200/go.23.00182}
}
Kostenlos starten →